Metagenomi (MGX) Projected to Post Quarterly Earnings on Tuesday

Metagenomi (NASDAQ:MGX - Get Free Report) is anticipated to release its Q1 2025 earnings data before the market opens on Tuesday, May 13th. Analysts expect Metagenomi to post earnings of ($0.62) per share for the quarter.

Metagenomi (NASDAQ:MGX - Get Free Report) last posted its quarterly earnings results on Monday, March 17th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.01). Metagenomi had a negative return on equity of 43.23% and a negative net margin of 134.27%. The company had revenue of $9.61 million during the quarter, compared to the consensus estimate of $13.18 million. During the same quarter in the prior year, the business earned ($20.05) earnings per share. On average, analysts expect Metagenomi to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Metagenomi Stock Performance

MGX traded down $0.06 during midday trading on Tuesday, reaching $1.51. 16,170 shares of the company were exchanged, compared to its average volume of 770,751. The stock has a market capitalization of $56.45 million, a P/E ratio of -0.58 and a beta of -0.65. The stock's 50-day simple moving average is $1.66 and its 200 day simple moving average is $2.30. Metagenomi has a one year low of $1.23 and a one year high of $8.17.

Institutional Investors Weigh In On Metagenomi

An institutional investor recently raised its position in Metagenomi stock. Bank of America Corp DE boosted its position in shares of Metagenomi, Inc. (NASDAQ:MGX - Free Report) by 482.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,113 shares of the company's stock after purchasing an additional 17,491 shares during the period. Bank of America Corp DE owned about 0.06% of Metagenomi worth $76,000 at the end of the most recent reporting period.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. HC Wainwright lowered their target price on shares of Metagenomi from $14.00 to $7.00 and set a "buy" rating for the company in a research note on Thursday, April 3rd. Wells Fargo & Company lowered their price objective on shares of Metagenomi from $25.00 to $20.00 and set an "overweight" rating for the company in a research report on Tuesday, March 18th.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.